-
1
-
-
0025256091
-
Amphotericin B: 30 years of clinical experience
-
GALLIS HA, DREW RH, PICKARD WW: Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. (1990) 12(2):308-329.
-
(1990)
Rev. Infect. Dis.
, vol.12
, Issue.2
, pp. 308-329
-
-
Gallis, H.A.1
Drew, R.H.2
Pickard, W.W.3
-
2
-
-
0027321730
-
Immunomodulating activity of antifungal drugs
-
YAMAGUCHI H, ABE S, TOKUDA Y: Immunomodulating activity of antifungal drugs. Ann. NY Acad. Sci. (1993) 685:447-457.
-
(1993)
Ann. NY Acad. Sci.
, vol.685
, pp. 447-457
-
-
Yamaguchi, H.1
Abe, S.2
Tokuda, Y.3
-
3
-
-
0028031883
-
Oral azole drugs as systemic antifungal therapy
-
COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330(4):263-272.
-
(1994)
N. Engl. J. Med.
, vol.330
, Issue.4
, pp. 263-272
-
-
Como, J.A.1
Dismukes, W.E.2
-
4
-
-
0032927254
-
Drug, meal and formulation interactions influencing drug absorption after oral administration: Clinical implications
-
FLEISHER D, LI C, ZHOU Y, KARIM A: Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin. Pharmacokinet. (1999) 36(3):233-254.
-
(1999)
Clin. Pharmacokinet.
, vol.36
, Issue.3
, pp. 233-254
-
-
Fleisher, D.1
Li, C.2
Zhou, Y.3
Karim, A.4
-
6
-
-
0024847184
-
The clinical pharmacokinetics of itraconazole: An overview
-
HEYKANTS J, VAN PEER A, VAN DE VELDE V et al.: The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 32(Suppl. 1):67-87.
-
(1989)
Mycoses
, vol.32
, Issue.SUPPL. 1
, pp. 67-87
-
-
Heykants, J.1
Van Peer, A.2
Van De Velde, V.3
-
7
-
-
4644321613
-
Role of itraconazole metabolites in CYP3A4 inhibition
-
ISOHERRANEN N, KUNZE KL, ALLEN KE, NELSON WL, THUMMEL KE: Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Disp. (2004) 32(10):1121-1131.
-
(2004)
Drug Metab. Disp.
, vol.32
, Issue.10
, pp. 1121-1131
-
-
Isoherranen, N.1
Kunze, K.L.2
Allen, K.E.3
Nelson, W.L.4
Thummel, K.E.5
-
8
-
-
0037371098
-
Voriconazole: A new triazole antifungal
-
PEARSON MM, ROGERS PD, CLEARY JD, CHAPMAN SW: Voriconazole: a new triazole antifungal. Ann. Pharmacotherapy (2003) 37(3):420-432.
-
(2003)
Ann. Pharmacotherapy
, vol.37
, Issue.3
, pp. 420-432
-
-
Pearson, M.M.1
Rogers, P.D.2
Cleary, J.D.3
Chapman, S.W.4
-
9
-
-
0037371527
-
Voriconazole: A new triazole antifungal agent
-
JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630-637.
-
(2003)
Clin. Infect. Dis.
, vol.36
, Issue.5
, pp. 630-637
-
-
Johnson, L.B.1
Kauffman, C.A.2
-
10
-
-
0037403687
-
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
-
HYLAND R, JONES BC, SMITH DA: Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Disp. (2003) 31(5):540-547.
-
(2003)
Drug Metab. Disp.
, vol.31
, Issue.5
, pp. 540-547
-
-
Hyland, R.1
Jones, B.C.2
Smith, D.A.3
-
11
-
-
0034792584
-
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
-
GOLDSTEIN JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. (2001) 52(4):349-355.
-
(2001)
Br. J. Clin. Pharmacol.
, vol.52
, Issue.4
, pp. 349-355
-
-
Goldstein, J.A.1
-
12
-
-
0036263813
-
Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data
-
LEE CR, GOLDSTEIN JA, PIEPER JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics (2002) 12(3):251-263.
-
(2002)
Pharmacogenetics
, vol.12
, Issue.3
, pp. 251-263
-
-
Lee, C.R.1
Goldstein, J.A.2
Pieper, J.A.3
-
14
-
-
0031748173
-
In vitro and in vivo drug interactions involving human CYP3A
-
THUMMEL KE, WILKINSON GR: In vitro and in vivo drug interactions involving human CYP3A. Ann. Rev. Pharmacol. Toxicol. (1998) 38:389-430.
-
(1998)
Ann. Rev. Pharmacol. Toxicol.
, vol.38
, pp. 389-430
-
-
Thummel, K.E.1
Wilkinson, G.R.2
-
15
-
-
0031423883
-
Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro
-
OMAR G, WHITING PH, HAWKSWORTH GM, HUMPHREY MJ, BURKE MD: Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther. Drug Monit. (1997) 19(4):436-445.
-
(1997)
Ther. Drug Monit.
, vol.19
, Issue.4
, pp. 436-445
-
-
Omar, G.1
Whiting, P.H.2
Hawksworth, G.M.3
Humphrey, M.J.4
Burke, M.D.5
-
16
-
-
0036957299
-
Voriconazole in the treatment of invasive aspergillosis
-
MUIJSERS RB, GOA KL, SCOTT LJ: Voriconazole in the treatment of invasive aspergillosis. Drugs (2002) 62(18):2655-2664.
-
(2002)
Drugs
, vol.62
, Issue.18
, pp. 2655-2664
-
-
Muijsers, R.B.1
Goa, K.L.2
Scott, L.J.3
-
17
-
-
0029996292
-
Warfarin-fluconazole II. A metabolically based drug interaction: In vivo studies
-
BLACK DJ, KUNZE KL, WIENKERS LC et al.: Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab. Disp. (1996) 24(4):422-428.
-
(1996)
Drug Metab. Disp.
, vol.24
, Issue.4
, pp. 422-428
-
-
Black, D.J.1
Kunze, K.L.2
Wienkers, L.C.3
-
18
-
-
0036135397
-
Interaction of common azole antifungals with P-glycoprotein
-
WANG EJ, LEW K, CASCIANO CN, CLEMENT RP, JOHNSON WW: Interaction of common azole antifungals with P-glycoprotein. Antimicrob. Agents Chemother. (2002) 46(1):160-165.
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, Issue.1
, pp. 160-165
-
-
Wang, E.J.1
Lew, K.2
Casciano, C.N.3
Clement, R.P.4
Johnson, W.W.5
-
19
-
-
0029028792
-
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
-
WACHER VJ, WU CJ, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. (1995) 13(3):129-134.
-
(1995)
Mol. Carcinogen.
, vol.13
, Issue.3
, pp. 129-134
-
-
Wacher, V.J.1
Wu, C.J.2
Benet, L.Z.3
-
20
-
-
0031765907
-
Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics
-
WACHER VJ, SILVERMAN JA, ZHANG Y, BENET LZ: Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. (1998) 87(11):1322-1330.
-
(1998)
J. Pharm. Sci.
, vol.87
, Issue.11
, pp. 1322-1330
-
-
Wacher, V.J.1
Silverman, J.A.2
Zhang, Y.3
Benet, L.Z.4
-
21
-
-
0345411341
-
P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies
-
WANDEL C, KIM RB, KAJIJI S, GUENGERICH P, WILKINSON GR, WOOD AJ: P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. (1999) 59(16):3944-3948.
-
(1999)
Cancer Res.
, vol.59
, Issue.16
, pp. 3944-3948
-
-
Wandel, C.1
Kim, R.B.2
Kajiji, S.3
Guengerich, P.4
Wilkinson, G.R.5
Wood, A.J.6
-
22
-
-
17544365536
-
The role of passive transbilayer drug movement in multidrug resistance and its modulation
-
EYTAN GD, REGEV R, OREN G, ASSARAF YG: The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. (1996) 271(22):12897-12902.
-
(1996)
J. Biol. Chem.
, vol.271
, Issue.22
, pp. 12897-12902
-
-
Eytan, G.D.1
Regev, R.2
Oren, G.3
Assaraf, Y.G.4
-
23
-
-
0033969525
-
Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane
-
FERTE J: Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. (2000) 267(2):277-294.
-
(2000)
Eur. J. Biochem.
, vol.267
, Issue.2
, pp. 277-294
-
-
Ferte, J.1
-
24
-
-
0344512413
-
Voriconazole does not affect the steady-state pharmacokinetics of digoxin
-
PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):45-50.
-
(2003)
Br. J. Clin. Pharmacol.
, vol.56
, Issue.SUPPL. 1
, pp. 45-50
-
-
Purkins, L.1
Wood, N.2
Kleinermans, D.3
Nichols, D.4
-
25
-
-
0033787342
-
Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine
-
BALANI SK, XU X, ARISON BH, SILVA MV, GRIES A, DELUNA FA et al.: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Disp. (2000) 28(11):1274-1278.
-
(2000)
Drug Metab. Disp.
, vol.28
, Issue.11
, pp. 1274-1278
-
-
Balani, S.K.1
Xu, X.2
Arison, B.H.3
Silva, M.V.4
Gries, A.5
Deluna, F.A.6
-
27
-
-
4644320394
-
Micafungin
-
CARVER PL: Micafungin. Ann. Pharmacotherapy (2004) 38(10):1707-1721.
-
(2004)
Ann. Pharmacotherapy
, vol.38
, Issue.10
, pp. 1707-1721
-
-
Carver, P.L.1
-
28
-
-
0003339063
-
A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen
-
Toronto, Ontario, Canada Abstract 854
-
STONE JA, MCCREA JB, WICKERSHAM PJ et al.: A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. Program & Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) Abstract 854.
-
(2000)
Program & Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Stone, J.A.1
McCrea, J.B.2
Wickersham, P.J.3
-
29
-
-
0028273122
-
Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
-
ZIMMERMAN T, YEATES RA, LAUFEN H, PFAFF G, WILDFEUER A: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol. (1994) 46(2):147-150.
-
(1994)
Eur. J. Clin. Pharmacol.
, vol.46
, Issue.2
, pp. 147-150
-
-
Zimmerman, T.1
Yeates, R.A.2
Laufen, H.3
Pfaff, G.4
Wildfeuer, A.5
-
30
-
-
0037326511
-
A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution
-
JOHNSON MD, HAMILTON CD, DREW RH, SANDERS LL, PENNICK GJ, PERFECT JR: A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J. Antimicrob. Chemother. (2003) 51(2):453-457.
-
(2003)
J. Antimicrob. Chemother.
, vol.51
, Issue.2
, pp. 453-457
-
-
Johnson, M.D.1
Hamilton, C.D.2
Drew, R.H.3
Sanders, L.L.4
Pennick, G.J.5
Perfect, J.R.6
-
31
-
-
0031765677
-
Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: The effect of famotidine on the absorption of itraconazole
-
KANDA Y, KAMI M, MATSUYAMA T et al.: Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol. Oncol. (1998) 16(1):33-37.
-
(1998)
Hematol. Oncol.
, vol.16
, Issue.1
, pp. 33-37
-
-
Kanda, Y.1
Kami, M.2
Matsuyama, T.3
-
32
-
-
0027175695
-
Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity
-
LIM SG, SAWYERR AM, HUDSON M, SERCOMBE J, POUNDER RE: Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol. Ther. (1993) 7(5):317-321.
-
(1993)
Aliment. Pharmacol. Ther.
, vol.7
, Issue.5
, pp. 317-321
-
-
Lim, S.G.1
Sawyerr, A.M.2
Hudson, M.3
Sercombe, J.4
Pounder, R.E.5
-
33
-
-
0031922837
-
Effect of omeprazole on the pharmacokinetics of itraconazole
-
JARURATANASIRIKUL S, SRIWIRIYAJAN S: Effect of omeprazole on the pharmacokinetics of itraconazole. Eur. J. Clin. Pharmacol. (1998) 54(2):159-161.
-
(1998)
Eur. J. Clin. Pharmacol.
, vol.54
, Issue.2
, pp. 159-161
-
-
Jaruratanasirikul, S.1
Sriwiriyajan, S.2
-
34
-
-
0028060606
-
Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers
-
MAY DB, DREW RH, YEDINAK KC, BARLETT JA: Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy (1994) 14(5):509-513.
-
(1994)
Pharmacotherapy
, vol.14
, Issue.5
, pp. 509-513
-
-
May, D.B.1
Drew, R.H.2
Yedinak, K.C.3
Barlett, J.A.4
-
35
-
-
0036097706
-
Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole
-
DAMLE B, HESS H, KAUL S, KNUPP C: Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm. Drug Disp. (2002) 23(2):59-66.
-
(2002)
Biopharm. Drug Disp.
, vol.23
, Issue.2
, pp. 59-66
-
-
Damle, B.1
Hess, H.2
Kaul, S.3
Knupp, C.4
-
36
-
-
0031736655
-
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
-
CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. (1998) 80(1):1-34.
-
(1998)
Pharmacol. Ther.
, vol.80
, Issue.1
, pp. 1-34
-
-
Christians, U.1
Jacobsen, W.2
Floren, L.C.3
-
37
-
-
0000626919
-
ZD4522-An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
-
[abstract]
-
MCCORMICK AD, MCKILLOP D, BUTTERS CJ et al.: ZD4522-An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J. Clin. Pharmacol. (2000) 40(10):1055.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, Issue.10
, pp. 1055
-
-
McCormick, A.D.1
McKillop, D.2
Butters, C.J.3
-
38
-
-
0032911163
-
Comparison of cytochrome P450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver
-
JACOBSEN W, KIRCHNER G, HALLENSLEBEN K et al.: Comparison of cytochrome P450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Disp. (1999) 27(2):173-179.
-
(1999)
Drug Metab. Disp.
, vol.27
, Issue.2
, pp. 173-179
-
-
Jacobsen, W.1
Kirchner, G.2
Hallensleben, K.3
-
39
-
-
0032438509
-
Optimization of itraconazole therapy using target drug concentrations
-
POIRIER JM, CHEYMOL G: Optimization of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. (1998) 35(6):461-473.
-
(1998)
Clin. Pharmacokinet.
, vol.35
, Issue.6
, pp. 461-473
-
-
Poirier, J.M.1
Cheymol, G.2
-
40
-
-
0029758869
-
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
-
NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. (1996) 60(1):54-61.
-
(1996)
Clin. Pharmacol. Ther.
, vol.60
, Issue.1
, pp. 54-61
-
-
Neuvonen, P.J.1
Jalava, K.M.2
-
41
-
-
0031892901
-
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
-
NEUVONEN PJ, KANTOLA T, KIVISTÖ KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (1998) 63(3):332-341.
-
(1998)
Clin. Pharmacol. Ther.
, vol.63
, Issue.3
, pp. 332-341
-
-
Neuvonen, P.J.1
Kantola, T.2
Kivistö, K.T.3
-
42
-
-
0031847115
-
Effect of itraconazole on the pharmacokinetics of atorvastatin
-
KANTOLA T, KIVISTÖ KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. (1998) 64(1):58-65.
-
(1998)
Clin. Pharmacol. Ther.
, vol.64
, Issue.1
, pp. 58-65
-
-
Kantola, T.1
Kivistö, K.T.2
Neuvonen, P.J.3
-
43
-
-
0033745108
-
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
-
MAZZU AL, LASSETER KC, SHAMBLIN EC, AGARWAL V, LETTIERI J, SUNDARESEN P: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther. (2000) 68(4):391-400.
-
(2000)
Clin. Pharmacol. Ther.
, vol.68
, Issue.4
, pp. 391-400
-
-
Mazzu, A.L.1
Lasseter, K.C.2
Shamblin, E.C.3
Agarwal, V.4
Lettieri, J.5
Sundaresen, P.6
-
44
-
-
0034961379
-
Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions
-
ISHIGAM M, UCHIYAMA M, KONDO T et al.: Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm. Res. (2001) 18(5):622-631.
-
(2001)
Pharm. Res.
, vol.18
, Issue.5
, pp. 622-631
-
-
Ishigam, M.1
Uchiyama, M.2
Kondo, T.3
-
45
-
-
0031803373
-
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
-
KIVISTÖ KT, KANTOLA T, NEUVONEN PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. (1998) 46(1):49-53.
-
(1998)
Br. J. Clin. Pharmacol.
, vol.46
, Issue.1
, pp. 49-53
-
-
Kivistö, K.T.1
Kantola, T.2
Neuvonen, P.J.3
-
46
-
-
0344453812
-
Effect of itraconazole on the pharmacokinetics of rosuvastatin
-
COOPER KJ, MARTIN PD, DANE AL, WARWICK MJ, SCHNECK DW, CANTARINI MV: Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. (2003) 73(4):322-329.
-
(2003)
Clin. Pharmacol. Ther.
, vol.73
, Issue.4
, pp. 322-329
-
-
Cooper, K.J.1
Martin, P.D.2
Dane, A.L.3
Warwick, M.J.4
Schneck, D.W.5
Cantarini, M.V.6
-
47
-
-
0032949332
-
Molecular and physical mechanisms of first-pass extraction
-
HALL SD, THUMMEL KE, WATKINS PB et al.: Molecular and physical mechanisms of first-pass extraction. Drug Metab. Disp. (1999) 27(2):161-166.
-
(1999)
Drug Metab. Disp.
, vol.27
, Issue.2
, pp. 161-166
-
-
Hall, S.D.1
Thummel, K.E.2
Watkins, P.B.3
-
48
-
-
0028568243
-
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
-
VARHE A, OLKKOLA KT, NEUVONEN PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. (1994) 56(6):601-607.
-
(1994)
Clin. Pharmacol. Ther.
, vol.56
, Issue.6
, pp. 601-607
-
-
Varhe, A.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
49
-
-
0029664974
-
The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
-
OLKKOLA KT, AHONEN J, NEUVONEN PJ: The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. (1996) 82(3):511-516.
-
(1996)
Anesth. Analg.
, vol.82
, Issue.3
, pp. 511-516
-
-
Olkkola, K.T.1
Ahonen, J.2
Neuvonen, P.J.3
-
50
-
-
0029810767
-
The effect of ingestion time interval on the interaction between itraconazole and triazolam
-
NEUVONEN PJ, VARHE A, OLKKOLA KT: The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin. Pharmacol. Ther. 1996 60(3):326-331.
-
(1996)
Clin. Pharmacol. Ther.
, vol.60
, Issue.3
, pp. 326-331
-
-
Neuvonen, P.J.1
Varhe, A.2
Olkkola, K.T.3
-
51
-
-
0031959294
-
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
-
BACKMAN JT, KIVISTÖ KT, OLKKOLA KT, NEUVONEN PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. (1998) 54(1):53-58.
-
(1998)
Eur. J. Clin. Pharmacol.
, vol.54
, Issue.1
, pp. 53-58
-
-
Backman, J.T.1
Kivistö, K.T.2
Olkkola, K.T.3
Neuvonen, P.J.4
-
52
-
-
0029906407
-
The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam
-
AHONEN J, OLKKOLA KT, NEUVONEN PJ: The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam. Clin. Pharmacol. (1996) 10(3):314-318.
-
(1996)
Fundam. Clin. Pharmacol.
, vol.10
, Issue.3
, pp. 314-318
-
-
Ahonen, J.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
53
-
-
0029878797
-
Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam
-
AHONEN J, OLKKOLA KT, NEUVONEN PJ: Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther. Drug Monit. (1996) 18(2):124-127.
-
(1996)
Ther. Drug Monit.
, vol.18
, Issue.2
, pp. 124-127
-
-
Ahonen, J.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
54
-
-
0344303626
-
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers
-
ODA M, KOTEGAWA T, TSUTSUMI K, OHTANI Y, KUWATANI K, NAKANO S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur. J. Clin. Pharmacol. (2003) 59(8-9):615-619.
-
(2003)
Eur. J. Clin. Pharmacol.
, vol.59
, Issue.8-9
, pp. 615-619
-
-
Oda, M.1
Kotegawa, T.2
Tsutsumi, K.3
Ohtani, Y.4
Kuwatani, K.5
Nakano, S.6
-
55
-
-
0036001235
-
No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam
-
OTSUJI Y, OKUYAMA N, AOSHIMA T et al.: No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther. Drug Monit. (2002) 24(3):375-378.
-
(2002)
Ther. Drug Monit.
, vol.24
, Issue.3
, pp. 375-378
-
-
Otsuji, Y.1
Okuyama, N.2
Aoshima, T.3
-
56
-
-
0030882158
-
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole
-
KIVISTÖ KT, LAMBERG TS, KANTOLA T, NEUVONEN PJ: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. (1997) 62(3):348-354.
-
(1997)
Clin. Pharmacol. Ther.
, vol.62
, Issue.3
, pp. 348-354
-
-
Kivistö, K.T.1
Lamberg, T.S.2
Kantola, T.3
Neuvonen, P.J.4
-
57
-
-
0031954051
-
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem
-
LUURILA H, KIVISTÖ KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. (1998) 54(2):163-166.
-
(1998)
Eur. J. Clin. Pharmacol.
, vol.54
, Issue.2
, pp. 163-166
-
-
Luurila, H.1
Kivistö, K.T.2
Neuvonen, P.J.3
-
58
-
-
0031466520
-
Interactions between tacrolimus and antimicrobial agents
-
PATERSON DL, SINGH N: Interactions between tacrolimus and antimicrobial agents. Clin. Infect. Dis. (1997) 25(6):1430-1440.
-
(1997)
Clin. Infect. Dis.
, vol.25
, Issue.6
, pp. 1430-1440
-
-
Paterson, D.L.1
Singh, N.2
-
59
-
-
0031939246
-
Systemic antifungal agents: Drug interactions of clinical significance
-
ALBENGRES E, LE LOUËT H, TILLEMENT JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. (1998) 18(2):83-97.
-
(1998)
Drug Saf.
, vol.18
, Issue.2
, pp. 83-97
-
-
Albengres, E.1
Le Louët, H.2
Tillement, J.P.3
-
60
-
-
0030042485
-
Clinically significant drug interactions with cyclosporin: An update. cyclosporine with antimicrobial agents
-
CAMPANA C, REGAZZI MB, BUGGIA I, MOLINARO M: Clinically significant drug interactions with cyclosporin: an update. cyclosporine with antimicrobial agents. Clin. Pharmacokinet. (1996) 30(2):141-179.
-
(1996)
Clin. Pharmacokinet.
, vol.30
, Issue.2
, pp. 141-179
-
-
Campana, C.1
Regazzi, M.B.2
Buggia, I.3
Molinaro, M.4
-
61
-
-
0024995451
-
Cyclosporine and itraconazole in heart and lung transplant recipients
-
KRAMER MR, MARSHALL SE, DENNING DW et al.: Cyclosporine and itraconazole in heart and lung transplant recipients. Ann. Intern. Med. (1990) 113(4):327-329.
-
(1990)
Ann. Intern. Med.
, vol.113
, Issue.4
, pp. 327-329
-
-
Kramer, M.R.1
Marshall, S.E.2
Denning, D.W.3
-
62
-
-
0031671850
-
Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients
-
BILLAUD EM, GUILLEMAIN R, TACCO F, CHEVALIER P: Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br. J. Clin. Pharmacol. (1998) 46(3):271-272.
-
(1998)
Br. J. Clin. Pharmacol.
, vol.46
, Issue.3
, pp. 271-272
-
-
Billaud, E.M.1
Guillemain, R.2
Tacco, F.3
Chevalier, P.4
-
63
-
-
0031660264
-
Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole
-
VARIS T, KAUKONEN KM, KIVISTÖ KT, NEUVONEN PJ: Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin. Pharmacol. Ther. (1998) 64(4):363-368.
-
(1998)
Clin. Pharmacol. Ther.
, vol.64
, Issue.4
, pp. 363-368
-
-
Varis, T.1
Kaukonen, K.M.2
Kivistö, K.T.3
Neuvonen, P.J.4
-
64
-
-
0034856667
-
Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects
-
LEBRUN-VIGNES B, ARCHER VC, DIQUET B et al.: Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br. J. Clin. Pharmacol. (2001) 51(5):443-450.
-
(2001)
Br. J. Clin. Pharmacol.
, vol.51
, Issue.5
, pp. 443-450
-
-
Lebrun-Vignes, B.1
Archer, V.C.2
Diquet, B.3
-
65
-
-
0032967254
-
Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers
-
VARIS T, KIVISTÖ KT, BACKMAN JT, NEUVONEN PJ: Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol. Toxicol. (1999) 85(1):29-32.
-
(1999)
Pharmacol. Toxicol.
, vol.85
, Issue.1
, pp. 29-32
-
-
Varis, T.1
Kivistö, K.T.2
Backman, J.T.3
Neuvonen, P.J.4
-
66
-
-
0033681559
-
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect
-
VARIS T, KIVISTÖ KT, BACKMAN JT, NEUVONEN PJ: The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin. Pharmacol. Ther. (2000) 68(5):487-494.
-
(2000)
Clin. Pharmacol. Ther.
, vol.68
, Issue.5
, pp. 487-494
-
-
Varis, T.1
Kivistö, K.T.2
Backman, J.T.3
Neuvonen, P.J.4
-
67
-
-
0034071745
-
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone
-
VARIS T, KIVISTÖ KT, NEUVONEN PJ: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur. J. Clin. Pharmacol. (2000) 56(1):57-60.
-
(2000)
Eur. J. Clin. Pharmacol.
, vol.56
, Issue.1
, pp. 57-60
-
-
Varis, T.1
Kivistö, K.T.2
Neuvonen, P.J.3
-
68
-
-
0036795133
-
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P450 3A4 inhibitor itraconazole
-
RAASKA K, NIEMI M, NEUVONEN M, NEUVONEN PJ, KIVISTÖ KT: Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P450 3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (2002) 72(4):362-369.
-
(2002)
Clin. Pharmacol. Ther.
, vol.72
, Issue.4
, pp. 362-369
-
-
Raaska, K.1
Niemi, M.2
Neuvonen, M.3
Neuvonen, P.J.4
Kivistö, K.T.5
-
69
-
-
0030898365
-
Itraconazole greatly increases plasma concentrations and effects of felodipine
-
JALAVA KM, OLKKOLA KT, NEUVONEN PJ: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. (1997) 61(4):410-415.
-
(1997)
Clin. Pharmacol. Ther.
, vol.61
, Issue.4
, pp. 410-415
-
-
Jalava, K.M.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
70
-
-
0031028102
-
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
-
AHONEN J, OLKKOLA KT, NEUVONEN PJ: Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. (1997) 51(5):415-419.
-
(1997)
Eur. J. Clin. Pharmacol.
, vol.51
, Issue.5
, pp. 415-419
-
-
Ahonen, J.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
71
-
-
0029981350
-
Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
-
VARHE A, OLKKOLA KT, NEUVONEN PJ: Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. (1996) 41(4):319-323.
-
(1996)
Br. J. Clin. Pharmacol.
, vol.41
, Issue.4
, pp. 319-323
-
-
Varhe, A.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
72
-
-
0029798201
-
Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
-
VARHE A, OLKKOLA KT, NEUVONEN PJ: Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br. J. Clin. Pharmacol. (1996) 42(4):465-470.
-
(1996)
Br. J. Clin. Pharmacol.
, vol.42
, Issue.4
, pp. 465-470
-
-
Varhe, A.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
73
-
-
0028341698
-
Fluconazole therapy in transplant recipients receiving FK506
-
MANEZ R, MARTIN M, RAMAN D et al.: Fluconazole therapy in transplant recipients receiving FK506. Transplantation (1994) 57(10):1521-1523.
-
(1994)
Transplantation
, vol.57
, Issue.10
, pp. 1521-1523
-
-
Manez, R.1
Martin, M.2
Raman, D.3
-
74
-
-
0024367870
-
Absence of significant interaction of fluconazole with cyclosporin
-
KRÜGER HU, SCHULER U, ZIMMERMANN R, EHNINGER G: Absence of significant interaction of fluconazole with cyclosporin. J. Antimicrob. Chemother. (1989) 24(5):781-786.
-
(1989)
J. Antimicrob. Chemother.
, vol.24
, Issue.5
, pp. 781-786
-
-
Krüger, H.U.1
Schuler, U.2
Zimmermann, R.3
Ehninger, G.4
-
75
-
-
0025893763
-
Interaction between cyclosporine and fluconazole in renal allograft recipients
-
CANAFAX DM, GRAVES NM, HILLIGOSS DM, CARLETON BC, GARDNER MJ, MATAS AJ: Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation (1991) 51(5):1014-1018.
-
(1991)
Transplantation
, vol.51
, Issue.5
, pp. 1014-1018
-
-
Canafax, D.M.1
Graves, N.M.2
Hilligoss, D.M.3
Carleton, B.C.4
Gardner, M.J.5
Matas, A.J.6
-
76
-
-
0027284797
-
Fluconazole-cyclosporine interaction: A dose-dependent effect?
-
LOPEZ-GIL JA: Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann. Pharmacotherapy (1993) 27(4):427-430.
-
(1993)
Ann. Pharmacotherapy
, vol.27
, Issue.4
, pp. 427-430
-
-
Lopez-Gil, J.A.1
-
77
-
-
0029913912
-
Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients
-
OSOWSKI CL, DIX SP, LIN LS, MULLINS RE, GELLER RB, WINGARD JR: Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients. Transplantation (1996) 61(8):1268-1272.
-
(1996)
Transplantation
, vol.61
, Issue.8
, pp. 1268-1272
-
-
Osowski, C.L.1
Dix, S.P.2
Lin, L.S.3
Mullins, R.E.4
Geller, R.B.5
Wingard, J.R.6
-
79
-
-
0031664160
-
Update on drug interactions with azole antifungal agents
-
LOMAESTRO BM, PIATEK MA: Update on drug interactions with azole antifungal agents. Ann. Pharmacotherapy (1998) 32(9):915-928.
-
(1998)
Ann. Pharmacotherapy
, vol.32
, Issue.9
, pp. 915-928
-
-
Lomaestro, B.M.1
Piatek, M.A.2
-
80
-
-
0344943294
-
Voriconazole potentiates warfarin-induced prothrombin time prolongation
-
PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):24-29.
-
(2003)
Br. J. Clin. Pharmacol.
, vol.56
, Issue.SUPPL. 1
, pp. 24-29
-
-
Purkins, L.1
Wood, N.2
Kleinermans, D.3
Nichols, D.4
-
81
-
-
0036227007
-
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients
-
ROMERO AJ, LE POGAMP P, NILSSON LG, WOOD N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin. Pharmacol. Ther. (2002) 71(4):226-234.
-
(2002)
Clin. Pharmacol. Ther.
, vol.71
, Issue.4
, pp. 226-234
-
-
Romero, A.J.1
Le Pogamp, P.2
Nilsson, L.G.3
Wood, N.4
-
82
-
-
0036720272
-
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes
-
VENKATARAMANAN R, ZANG S, GAYOWSKI T, SINGH N: Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob. Agents Chemother. (2002) 46(9):3091-3093.
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, Issue.9
, pp. 3091-3093
-
-
Venkataramanan, R.1
Zang, S.2
Gayowski, T.3
Singh, N.4
-
83
-
-
0037748569
-
Effect of voriconazole on the pharmacokinetics of tacrolimus
-
Chicago, IL, USA Abstract 20
-
WOOD N, TAN K, ALLAN R, FIELDING A, NICHOLS DJ: Effect of voriconazole on the pharmacokinetics of tacrolimus. Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001) Abstract 20.
-
(2001)
Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Wood, N.1
Tan, K.2
Allan, R.3
Fielding, A.4
Nichols, D.J.5
-
84
-
-
0344943289
-
Coadministration of voriconazole and phenytoin: Pharmacokinetic interaction, safety, and toleration
-
PURKINS L, WOOD N, GHAHRAMANI P, LOVE ER, EVE MD, FIELDING A: Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):37-44.
-
(2003)
Br. J. Clin. Pharmacol.
, vol.56
, Issue.SUPPL. 1
, pp. 37-44
-
-
Purkins, L.1
Wood, N.2
Ghahramani, P.3
Love, E.R.4
Eve, M.D.5
Fielding, A.6
-
85
-
-
0028276695
-
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
-
ANDERSSON T, MINERS JO, VERONESE ME, BIRKETT DJ: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. (1994) 37(6):597-604.
-
(1994)
Br. J. Clin. Pharmacol.
, vol.37
, Issue.6
, pp. 597-604
-
-
Andersson, T.1
Miners, J.O.2
Veronese, M.E.3
Birkett, D.J.4
-
86
-
-
0037748569
-
Effect of voriconazole on the pharmacokinetics of omeprazole
-
Chicago, IL, USA Abstract 19
-
WOOD N, TAN K, ALLAN R, FIELDING A, NICHOLS DJ: Effect of voriconazole on the pharmacokinetics of omeprazole. Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2001) Abstract 19.
-
(2001)
Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Wood, N.1
Tan, K.2
Allan, R.3
Fielding, A.4
Nichols, D.J.5
-
87
-
-
0038762840
-
The pharmacokinetics of voriconazole and its effect on prednisolone disposition
-
Toronto, Ontario, Canada Abstract 842
-
GHAHRAMANI P, PURKINS L, KLIENERMANS D, NICHOLS DJ: The pharmacokinetics of voriconazole and its effect on prednisolone disposition. Program & Abstracts 40st Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) Abstract 842.
-
(2000)
Program & Abstracts 40st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Ghahramani, P.1
Purkins, L.2
Klienermans, D.3
Nichols, D.J.4
-
88
-
-
0027102401
-
The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin
-
DE LANNOY IA, SILVERMAN M: The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Comm. (1992) 189(1):551-557.
-
(1992)
Biochem. Biophys. Res. Comm.
, vol.189
, Issue.1
, pp. 551-557
-
-
De Lannoy, I.A.1
Silverman, M.2
-
90
-
-
0037382845
-
Evaluation of P-glycoprotein mediated renal drug interactions in an MDR1-MDCK model
-
KARYEKAR CS, EDDINGTON ND, GARIMELLA TS, GUBBINS PO, DOWLING TC: Evaluation of P-glycoprotein mediated renal drug interactions in an MDR1-MDCK model. Pharmacotherapy (2003) 23(4):436-442.
-
(2003)
Pharmacotherapy
, vol.23
, Issue.4
, pp. 436-442
-
-
Karyekar, C.S.1
Eddington, N.D.2
Garimella, T.S.3
Gubbins, P.O.4
Dowling, T.C.5
-
92
-
-
0032779089
-
Effect of diclofenac, disulfram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine
-
DAMKIER P, HANSEN LL, BRØSEN K: Effect of diclofenac, disulfram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br. J. Clin. Pharmacol. (1999) 48(6):829-838.
-
(1999)
Br. J. Clin. Pharmacol.
, vol.48
, Issue.6
, pp. 829-838
-
-
Damkier, P.1
Hansen, L.L.2
Brøsen, K.3
-
93
-
-
0026467167
-
Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin
-
DE LANNOY IA, KOREN G, KLEIN J, CHARUK J, SILVERMAN M: Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am. J. Physiol. (1992) 263(4):F613-F622.
-
(1992)
Am. J. Physiol.
, vol.263
, Issue.4
-
-
De Lannoy, I.A.1
Koren, G.2
Klein, J.3
Charuk, J.4
Silverman, M.5
-
94
-
-
0038681693
-
Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole
-
ULLMAN AJ: Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opinion (2003) 19(4):263-271.
-
(2003)
Curr. Med. Res. Opinion
, vol.19
, Issue.4
, pp. 263-271
-
-
Ullman, A.J.1
-
95
-
-
0037339171
-
Caspofungin: The first representative of a new antifungal class
-
LETSCHER-BRU V, HERBRECHT R: Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. (2003) 51(3):513-521.
-
(2003)
J. Antimicrob. Chemother.
, vol.51
, Issue.3
, pp. 513-521
-
-
Letscher-Bru, V.1
Herbrecht, R.2
-
96
-
-
0003329322
-
Drug interactions between caspofungin and tacrolimus
-
Chicago, IL, USA Abstract 13
-
STONE J, HOLLAND S, WICKERSHAM P et al.: Drug interactions between caspofungin and tacrolimus. Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2001) Abstract 13.
-
(2001)
Program & Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Stone, J.1
Holland, S.2
Wickersham, P.3
-
97
-
-
3543095658
-
Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections
-
SANZ-RODRIGUEZ C, LOPEZ-DUARTE M, JURADO M et al.: Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. (2004) 34(1):13-20.
-
(2004)
Bone Marrow Transplant.
, vol.34
, Issue.1
, pp. 13-20
-
-
Sanz-Rodriguez, C.1
Lopez-Duarte, M.2
Jurado, M.3
-
98
-
-
7244258914
-
Potential for interactions between caspofungin and nelfinavir or rifampin
-
STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
-
(2004)
Antimicrob. Agents Chemother.
, vol.48
, pp. 4306-4314
-
-
Stone, J.A.1
Migoya, E.M.2
Hickey, L.3
|